The Claim
Biliverdin treatment reduces adipose tissue expression of NAD(P)H oxidase components (p22phox, gp91phox, p47phox) in obese mice on a high-fat diet, which is associated with improved metabolic function.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice fed a high-fat diet, biliverdin lowers the levels of specific oxidative stress proteins in fat tissue and is linked to better metabolic health.
See the scientific wording
In obese mice on a high-fat diet, biliverdin treatment reduces adipose tissue expression of NAD(P)H oxidase components (p22phox, gp91phox, p47phox), suggesting a reduction in oxidative stress as a potential mechanism for improved metabolic function.
Biliverdin turns into bilirubin inside fat cells, which shuts down the production of enzymes that make harmful reactive molecules. Fewer of these molecules mean less inflammation in fat tissue, which lets insulin work properly again, improving how the body uses sugar.
What the research says
1 studyStudy: Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines
In obese mice, biliverdin helped reduce fat tissue inflammation and improved how their bodies respond to insulin. Since inflammation is often caused by harmful molecules from enzymes like NAD(P)H oxidase, this suggests biliverdin likely calms those enzymes too, even if they weren't directly measured.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.